Abbott Laboratories (NYSE:ABT) Shares Sold by New Hampshire Trust

New Hampshire Trust lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,454 shares of the healthcare product maker’s stock after selling 242 shares during the quarter. New Hampshire Trust’s holdings in Abbott Laboratories were worth $2,012,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd acquired a new stake in Abbott Laboratories during the 4th quarter worth $28,000. Monumental Financial Group Inc. acquired a new position in shares of Abbott Laboratories during the 1st quarter valued at about $32,000. FWL Investment Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at about $33,000. True Wealth Design LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at about $33,000. Finally, Ridgewood Investments LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter valued at about $36,000. Institutional investors and hedge funds own 73.70% of the company’s stock.

Abbott Laboratories Stock Down 0.1 %

Shares of NYSE:ABT opened at $101.65 on Monday. Abbott Laboratories has a 1 year low of $93.25 and a 1 year high of $115.83. The firm has a market capitalization of $176.40 billion, a PE ratio of 34.72, a price-to-earnings-growth ratio of 4.59 and a beta of 0.68. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.64 and a quick ratio of 1.16. The firm’s 50-day moving average is $106.17 and its two-hundred day moving average is $105.24.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Abbott Laboratories had a return on equity of 20.50% and a net margin of 12.83%. The business had revenue of $9.98 billion during the quarter, compared to the consensus estimate of $9.71 billion. During the same period in the previous year, the company posted $1.43 earnings per share. The business’s revenue for the quarter was down 11.4% on a year-over-year basis. Analysts predict that Abbott Laboratories will post 4.4 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABT. Morgan Stanley reissued an “equal weight” rating and set a $112.00 price target on shares of Abbott Laboratories in a research report on Friday, July 21st. Wolfe Research upgraded shares of Abbott Laboratories from an “underperform” rating to a “peer perform” rating in a report on Friday, July 21st. Barclays boosted their price objective on shares of Abbott Laboratories from $127.00 to $132.00 and gave the company an “overweight” rating in a report on Monday, July 24th. StockNews.com started coverage on shares of Abbott Laboratories in a report on Thursday, August 17th. They issued a “buy” rating on the stock. Finally, Mizuho boosted their price objective on shares of Abbott Laboratories from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $120.82.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks sold 50,000 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $113.76, for a total transaction of $5,688,000.00. Following the completion of the transaction, the director now directly owns 6,775,316 shares of the company’s stock, valued at $770,759,948.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Daniel J. Starks sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $113.76, for a total value of $5,688,000.00. Following the completion of the transaction, the director now directly owns 6,775,316 shares of the company’s stock, valued at $770,759,948.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrea F. Wainer sold 10,400 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $105.03, for a total value of $1,092,312.00. Following the completion of the transaction, the executive vice president now directly owns 65,027 shares of the company’s stock, valued at $6,829,785.81. The disclosure for this sale can be found here. Corporate insiders own 1.10% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.